Otivio is a supplier of medical equipment that has developed an innovative system for the treatment of blood flow deficiency. The company has focused on improving patient care through technology, and their product, FlowOx™, has shown promising results in early studies. These studies indicate the potential for symptom relief in patients with multiple sclerosis, which may have an impact on their quality of life.
The company has also conducted the first randomized controlled trial documenting improved walking capacity in patients using their system. Otivio emphasizes the personalization of treatment, and offers patient stories that provide insight into the experiences of users of FlowOx™. In addition, Otivio is actively engaged in health and technology research and development, which underlines their commitment to improving treatment methods and patient outcomes.
